Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a ...
Abstract: One of the most critical parts of Electric Vehicles (EVs) is the Battery Management System (BMS). Replacing the traditional wired bus of the BMS by a wireless network brings several benefits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback